サリバ・パロチン・Aの抗原性について
スポンサーリンク
概要
- 論文の詳細を見る
Anti-saliva Parotin-A serum was obtained after the administration of saliva Parotin-A (SPA) to intact rabbits in the following doses : 10 μg./kg. for 10 days, 100 μg./kg. on the 11th day, 1 mg. on the 42nd day, and 2 mg. on the 54th day. By the technique of Ouchterlony, the antiserum obtained showed a precipitin band against SPA, but was not reactive to Parotin, S-Parotin, α-Uroparotin, β-Uroparotin, lyophylized saliva, etc., showing immunological specificity of the antiserum. The quantitative precipitin tests indicated that 1 ml. of the antiserum corresponded to 300 μg. of SPA. Administration of SPA mixed with the antiserum was found to be as effective as SPA alone upon the circulating leucocytes, while the antiserum itself showed no significant influence upon them. After mixing SPA with the antiserum in a ratio which ensured complete precipitation of SPA, the precipitate as well as the supernatant showed leucocyte-promoting activitiy. Besides this activity, the precipitate reduced the circulating lymphocytes, while the supernatant increased the granulocytes more markedly. These results suggest that the SPA used in this study contained at least two components ; one was precipitated by the antiserum and, after precipitation, still retained its leucocyte-promoting activity and the other was not precipitated. It was also found that the antigenic center of SPA would be different from the leucocyte-promoting activity in the molecules.
- 公益社団法人日本薬学会の論文
- 1966-04-25
著者
関連論文
- Radioprotective Effect of Pyridoxamine-5-thiophosphate and Related Compounds
- 放射線障害防護薬剤に関する研究(第7報) : AETおよびその関連化合物の放射線障害防護効力について
- Serum Levels of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) in Subjects Accidentally Exposed to ^Ir Gamma rays
- 放射線障害防護薬剤に関する研究(第17報)フェネチラミン系化合物の放射線障害防護効力について
- Increase of Survival of X-Irradiated Mice by Postirradiation Injections of a Splenic Extract Prepared from Vaccine or Endotoxin-treated Syngenic Animals
- 放射線障害防護薬剤に関する研究(第14報)含イオウ化合物の放射線障害防護効力について
- 放射線障害防護薬剤に関する研究(第13報)放射線によるマウスの臓器重量の変化ならびに放射線障害防護物質の効果について
- Hypotensive and Radioprotective Properties of N^6-Substituted Adenosine Derivatives
- Radioprotective Potency of Thiazine and Thiazole Derivatives
- Radioprotective Effect of Sodium Hydrogen S-(2-L-Pyrrolidyl-methyl) phosphorothioate in Mice
- Durable Radioprotection by Oral Administration of 2-Aminoethanethiosulfuric Acid in Mice
- 放射線障害防護薬剤に関する研究(第6報) : 放射線によるマウスの体重変化を指標とする放射線障害防護薬剤の効力試験法の検討
- Radiation Protection of Mice by Mixtures of β-Mercaptoethylguanidine (MEG) and Cysteamine (MEA)
- Protection of Catalase from Radiation-inactivation by Adenosine and its Derivatives in Dilute Solution
- 放射線障害防護薬剤に関する研究(第4報) : ビタミンEおよびその誘導体の放射線障害防護効力について
- パロチンおよびS-パロチンによる白血球増加作用の検討
- サリバ・パロチン・Aによる白血球増加作用の検討
- サリバ・パロチン・Aの抗原性について
- β-subunit hCGのRadioimmunoassayによるヒト着床期より分娩後にいたる血中hCGの動態
- イモリ睾丸における雄性ホルモンの生合成(内分泌・生化学)
- 放射線障害防護薬剤に関する研究(第5報) : マウスによる放射線障害防護薬剤の効力試験法の検討
- 放射線障害防護薬剤に関する研究(第3報) : AETおよびMEAの放射線障害防護効力について
- 放射線障害防護薬剤に関する研究(第2報) : 放射線によるマウス体重の変化について
- 放射線障害防護薬剤に関する研究(第1報) : 放射線によるマウスの致死効果について